Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology
Spero Therapeutics, Inc. (SPRO)
Last spero therapeutics, inc. earnings: 3/16 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.sperotherapeutics.com/overview
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., April 12, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announced the appointment of Ian A. Critchley, Ph.D. as Head of Clinical Microbiology to lead Spero’s pre-clinical and clinical microbiology efforts. Dr. Critchley brings over 30 years of experience in anti-infective drug discovery and development to Spero. “I am pleased that Ian is joining Spero to provide leadership and expertise on microbiology for the Company,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. “Ian’s hiring is part of our strategic plan to build the organization needed to support SPR994 in our planned Phase 3 pivotal trial and beyond, as well as to run a robust clinical portfolio. He will play an integral part in helping us achieve our mission of bringing novel therapi
Show less
Read more
Impact Snapshot
Event Time:
SPRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRO alerts
High impacting Spero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SPRO
News
- Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year [Yahoo! Finance]Yahoo! Finance
- Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market? [Yahoo! Finance]Yahoo! Finance
SPRO
Earnings
- 3/13/24 - Beat
SPRO
Sec Filings
- 4/16/24 - Form ARS
- 4/16/24 - Form DEFA14A
- 4/16/24 - Form DEF
- SPRO's page on the SEC website